Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer

NCT01836120 is registered in ClinicalTrials.gov with Hebei Tumor Hospital as lead sponsor.

NCT NCT01836120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01836120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer
Lead sponsor
Hebei Tumor Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2013
Completion date
June 30, 2017
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer